Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer.

Chitmanee P, Tsang Y, Tharmalingam H, Hamada M, Alonzi R, Ostler P, Hughes R, Lowe G, Hoskin P.

Clin Oncol (R Coll Radiol). 2019 Nov 7. pii: S0936-6555(19)30457-1. doi: 10.1016/j.clon.2019.10.008. [Epub ahead of print]

PMID:
31708350
2.

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.

Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators.

Lancet Oncol. 2019 Nov;20(11):1531-1543. doi: 10.1016/S1470-2045(19)30569-8. Epub 2019 Sep 17.

3.

Single-centre Experience of Use of Radium 223 with Clinical Outcomes Based on Number of Cycles and Bone Marrow Toxicity.

Dadhania S, Alonzi R, Douglas S, Gogbashian A, Hughes R, Dalili D, Vasdev N, Adshead J, Lane T, Westbury C, Anyamene N, Ostler P, Hoskin P, Sharma A.

Anticancer Res. 2018 Sep;38(9):5423-5427. doi: 10.21873/anticanres.12873.

PMID:
30194198
4.

Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer.

Hoskin P, Rojas A, Ostler P, Hughes R, Alonzi R, Lowe G.

Radiother Oncol. 2017 Jul;124(1):56-60. doi: 10.1016/j.radonc.2017.06.014. Epub 2017 Jun 27.

PMID:
28666552
5.

Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease.

Bhattacharya IS, Woolf DK, Hughes RJ, Shah N, Harrison M, Ostler PJ, Hoskin PJ.

Br J Radiol. 2015 Apr;88(1048):20140712. doi: 10.1259/bjr.20140712. Epub 2015 Feb 13.

6.

Dosimetric analysis of urethral strictures following HDR (192)Ir brachytherapy as monotherapy for intermediate- and high-risk prostate cancer.

Díez P, Mullassery V, Dankulchai P, Ostler P, Hughes R, Alonzi R, Lowe G, Hoskin PJ.

Radiother Oncol. 2014 Dec;113(3):410-3. doi: 10.1016/j.radonc.2014.10.007. Epub 2014 Nov 26.

PMID:
25544648
7.

Prostate stereotactic body radiotherapy—first UK experience.

Tree AC, Ostler P, Hoskin P, Dankulchai P, Nariyangadu P, Hughes RJ, Wells E, Taylor H, Khoo VS, van As NJ.

Clin Oncol (R Coll Radiol). 2014 Dec;26(12):757-61. doi: 10.1016/j.clon.2014.08.007. Epub 2014 Sep 3.

PMID:
25193299
8.

High-dose-rate brachytherapy with two or three fractions as monotherapy in the treatment of locally advanced prostate cancer.

Hoskin P, Rojas A, Ostler P, Hughes R, Alonzi R, Lowe G, Bryant L.

Radiother Oncol. 2014 Jul;112(1):63-7. doi: 10.1016/j.radonc.2014.06.007. Epub 2014 Jul 10.

PMID:
25018002
9.

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I.

J Clin Oncol. 2014 Jan 10;32(2):76-82. doi: 10.1200/JCO.2012.48.5268. Epub 2013 Dec 9.

PMID:
24323035
10.

New horizons and hurdles for UK radiotherapy: can prostate stereotactic body radiotherapy show the way?

Tree A, Ostler P, van As N.

Clin Oncol (R Coll Radiol). 2014 Jan;26(1):1-3. doi: 10.1016/j.clon.2013.11.002. Epub 2013 Dec 2. No abstract available.

PMID:
24296326
11.

High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: acute toxicity.

Hoskin P, Rojas A, Ostler P, Hughes R, Alonzi R, Lowe G, Bryant L.

Radiother Oncol. 2014 Feb;110(2):268-71. doi: 10.1016/j.radonc.2013.09.025. Epub 2013 Nov 11.

PMID:
24231242
12.

Dosimetric predictors of biochemical control of prostate cancer in patients randomised to external beam radiotherapy with a boost of high dose rate brachytherapy.

Hoskin PJ, Rojas AM, Ostler PJ, Hughes R, Bryant L, Lowe GJ.

Radiother Oncol. 2014 Jan;110(1):110-3. doi: 10.1016/j.radonc.2013.08.043. Epub 2013 Oct 4.

PMID:
24100150
13.

The influence of prostate volume on outcome after high-dose-rate brachytherapy alone for localized prostate cancer.

Le H, Rojas A, Alonzi R, Hughes R, Ostler P, Lowe G, Bryant L, Hoskin P.

Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):270-4. doi: 10.1016/j.ijrobp.2013.05.022. Epub 2013 Jul 9.

PMID:
23849693
14.

Quality of life after radical radiotherapy for prostate cancer: longitudinal study from a randomised trial of external beam radiotherapy alone or in combination with high dose rate brachytherapy.

Hoskin PJ, Rojas AM, Ostler PJ, Hughes R, Lowe GJ, Bryant L.

Clin Oncol (R Coll Radiol). 2013 May;25(5):321-7. doi: 10.1016/j.clon.2013.01.001. Epub 2013 Feb 4.

PMID:
23384799
15.

Stereotactic body radiotherapy for oligometastases.

Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ.

Lancet Oncol. 2013 Jan;14(1):e28-37. doi: 10.1016/S1470-2045(12)70510-7. Review.

PMID:
23276369
16.

Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer.

Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L.

Radiother Oncol. 2012 May;103(2):217-22. doi: 10.1016/j.radonc.2012.01.007. Epub 2012 Feb 16.

17.

High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence.

Hoskin P, Rojas A, Lowe G, Bryant L, Ostler P, Hughes R, Milner J, Cladd H.

Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1376-84. doi: 10.1016/j.ijrobp.2011.04.031. Epub 2011 Jun 15.

PMID:
21680108
18.

Use of irradiated autologous bone in joint sparing endoprosthetic femoral replacement tumor surgery.

Vijayan S, Bartlett W, Lee R, Ostler P, Blunn GW, Cannon SR, Briggs TW.

Indian J Orthop. 2011 Mar;45(2):161-7. doi: 10.4103/0019-5413.77137.

19.

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial.

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; EPO-INT-47 Study Group.

Oncologist. 2010;15(9):935-43. doi: 10.1634/theoncologist.2009-0279. Epub 2010 Aug 26.

20.

I-125 seed planning: an alternative method of urethra definition.

Anderson C, Lowe G, Ostler P, Inchley D, Hardiman C, Wills R, Bryant L, Chapman C, Marchant N, Hoskin PJ.

Radiother Oncol. 2010 Jan;94(1):24-9. doi: 10.1016/j.radonc.2009.11.003. Epub 2009 Dec 11.

PMID:
20005590
21.

Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer.

Simnor T, Li S, Lowe G, Ostler P, Bryant L, Chapman C, Inchley D, Hoskin PJ.

Radiother Oncol. 2009 Nov;93(2):253-8. doi: 10.1016/j.radonc.2009.09.015. Epub 2009 Oct 23.

PMID:
19854524
22.

Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer.

Sequist LV, Fidias P, Heist RS, Ostler P, Muzikansky A, Lynch TJ.

J Thorac Oncol. 2009 Sep;4(9):1170-3. doi: 10.1097/JTO.0b013e3181b28efe.

23.

Report on the early efficacy and tolerability of I(125) permanent prostate brachytherapy from a UK multi-institutional database.

Mitchell DM, Mandall P, Bottomley D, Hoskin PJ, Logue JP, Ash D, Ostler P, Elliott T, Henry A, Wylie JP.

Clin Oncol (R Coll Radiol). 2008 Dec;20(10):738-44. doi: 10.1016/j.clon.2008.09.003. Epub 2008 Oct 31.

PMID:
18951769
24.

Aggressiveness of care in a prospective cohort of patients with advanced NSCLC.

Temel JS, McCannon J, Greer JA, Jackson VA, Ostler P, Pirl WF, Lynch TJ, Billings JA.

Cancer. 2008 Aug 15;113(4):826-33. doi: 10.1002/cncr.23620.

25.

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.

Jackman DM, Kindler HL, Yeap BY, Fidias P, Salgia R, Lucca J, Morse LK, Ostler PA, Johnson BE, Jänne PA.

Cancer. 2008 Aug 15;113(4):808-14. doi: 10.1002/cncr.23617.

26.

A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer.

Corner C, Rojas AM, Bryant L, Ostler P, Hoskin P.

Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):441-6. doi: 10.1016/j.ijrobp.2007.12.026. Epub 2008 Feb 4.

PMID:
18249501
27.

Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients.

Temel JS, Jackson VA, Billings JA, Dahlin C, Block SD, Buss MK, Ostler P, Fidias P, Muzikansky A, Greer JA, Pirl WF, Lynch TJ.

J Clin Oncol. 2007 Jun 10;25(17):2377-82.

PMID:
17557950
28.

High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial.

Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P.

Radiother Oncol. 2007 Aug;84(2):114-20. Epub 2007 May 24.

PMID:
17531335
29.

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.

Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA.

J Clin Oncol. 2007 Mar 1;25(7):760-6. Epub 2007 Jan 16.

PMID:
17228019
30.

High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer.

Chin YS, Bullard J, Bryant L, Bownes P, Ostler P, Hoskin PJ.

Clin Oncol (R Coll Radiol). 2006 Aug;18(6):474-9.

PMID:
16909971
31.

Can I look at my list? An evaluation of a 'prompt sheet' within an oncology outpatient clinic.

Glynne-Jones R, Ostler P, Lumley-Graybow S, Chait I, Hughes R, Grainger J, Leverton TJ.

Clin Oncol (R Coll Radiol). 2006 Jun;18(5):395-400.

PMID:
16817331
32.

Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?

Glynne-Jones R, Grainger J, Harrison M, Ostler P, Makris A.

Br J Cancer. 2006 Feb 13;94(3):363-71. Review.

33.

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.

Jänne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, Fidias P, Lynch TJ, Johnson BE.

Lung Cancer. 2004 May;44(2):221-30.

PMID:
15084387
34.

High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions.

Hoskin PJ, Bownes PJ, Ostler P, Walker K, Bryant L.

Radiother Oncol. 2003 Sep;68(3):285-8.

PMID:
13129636
35.

Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study.

Wirth LJ, Lucca J, Ostler P, Fidias P, Lynch C, Jänne PA, Herbst RS, Johnson BE, Sugarbaker DJ, Mathisen DJ, Lukanich JM, Choi NC, Berman SM, Skarin AT.

Clin Cancer Res. 2003 May;9(5):1698-704.

36.

A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.

Fidias P, Supko JG, Martins R, Boral A, Carey R, Grossbard M, Shapiro G, Ostler P, Lucca J, Johnson BE, Skarin A, Lynch TJ.

Clin Cancer Res. 2001 Dec;7(12):3942-9.

37.

The role of staging CT scans in the treatment of prostate cancer: a retrospective audit.

Burcombe RJ, Ostler PJ, Ayoub AW, Hoskin PJ.

Clin Oncol (R Coll Radiol). 2000;12(1):32-5.

PMID:
10749017
38.

Syringomyelia after chemotherapy and radiotherapy for advanced oropharyngeal carcinoma: cause or coincidence?

Ostler PJ, Patel N, Grant HR, Gaze MN.

Clin Oncol (R Coll Radiol). 1998;10(5):324-6.

PMID:
9848335
39.

Case report: Magnetic resonance imaging in primary cervical lymphoma: the role in diagnosis and follow-up.

Clarke DP, Ostler P, Watkinson A, Collis C, Berger L.

Clin Radiol. 1998 May;53(5):383-5. No abstract available.

PMID:
9630282
40.

Superior vena cava obstruction: a modern management strategy.

Ostler PJ, Clarke DP, Watkinson AF, Gaze MN.

Clin Oncol (R Coll Radiol). 1997;9(2):83-9. Review.

PMID:
9135892

Supplemental Content

Loading ...
Support Center